New antibody combo shows promise for tough ovarian cancer
NCT ID NCT04938583
First seen Apr 08, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix is safe and can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER STAGE IV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Hospital
Seoul, Seoul, 05505, South Korea
-
CHA Bundang Medical Center
Seongnam-si, 13496, South Korea
-
Korea Anam Hospital
Seoul, Seoul, 02841, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
Seoul St. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oregovomab (an antibody drug) combined with bevacizumab, paclitaxel, and carboplatin
What this could lead to
If successful, this combination could offer a new treatment option for women with recurrent ovarian cancer who have limited choices.
What could go wrong
This is an early-phase trial with only 54 participants, so results may not apply broadly. The combination also carries risks like side effects from chemotherapy and the antibody.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.